Loading the section
Closing prices for 09 October 2026
Next earnings report: 27 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Labcorp Holdings Inc. trades on NYSE under the ticker LH. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks LH has traded between 244.52 $ and 341.80 $. As of 09 October 2026 the price stood 69.52 % of the way from the 52-week low to the high.
Over one year LH shares rose 12.48 %; over six months they rose 19.63 %. Volatility over 90 days is 23.96 %. Dividends are not included: this is price change only, as of 09 October 2026.
LH trades at a price-to-earnings ratio of 27.5, above the sector median of 24.8. Price to sales is 1.8, below the sector median of 3.9. Price to book is 3.0, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 313.39 | 318.18 | 311.62 | 312.15 | 607,853 |
| 08 October 2026 | 312.34 | 315.48 | 309.04 | 314.20 | 703,700 |
| 07 October 2026 | 312.04 | 315.09 | 311.21 | 311.97 | 546,600 |
| 06 October 2026 | 310.41 | 312.76 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Labcorp runs laboratory tests on a doctor's referral — one of two networks covering the whole country.
The economics of a laboratory network are about utilisation: the analyser and the logistics cost the same whatever the number of samples, so each additional specimen flows almost entirely into profit. Hence the constant fight for volume and the purchase of hospital laboratories from institutions that find outsourcing cheaper than running their own department.
Price is dictated not by the market but by insurers and government programmes: a revised fee schedule can change the profitability of a whole line. The second part of the business is running clinical trials for drug companies. Risks: reimbursement rates, competition for insurer contracts and labour costs. The company pays a dividend.
Address:358 S MAIN ST, BURLINGTON, NC, 27215, US
Labcorp Holdings Inc. reported revenue of 14.1B $ and net income of 942M $ over the last four quarters. Net margin is 6.66 %. Revenue changed by +7.34 % year over year. Earnings per share are 11.29 $. Market capitalisation is 25.9B $.
LH has a return on equity of 10.79 %, above the sector median of −41.68 %. Return on assets is 4.93 %, above the sector median of −32.11 %. Operating margin is 10.18 %, above the sector median of −26.84 %.
| 145M |
| GRALGRAIL, Inc. | 141.86 | +6.98 % | 138M |
| CELCCelcuity Inc. | 67.68 | −0.28 % | 90M |
| CDNACareDx, Inc. | 63.71 | +2.42 % | 80M |
| BLLNBillionToOne, Inc. | 98.28 | +3.01 % | 66M |
| 304.92 |
| 311.71 |
| 987,800 |
| 05 October 2026 | 308.08 | 309.79 | 305.84 | 308.65 | 705,900 |
| 02 October 2026 | 305.77 | 309.36 | 302.71 | 308.49 | 588,200 |
| 01 October 2026 | 306.00 | 309.72 | 304.06 | 304.60 | 559,400 |
| 30 September 2026 | 311.00 | 311.54 | 306.98 | 308.11 | 646,200 |
| 29 September 2026 | 306.89 | 309.95 | 306.58 | 308.81 | 613,100 |
| 28 September 2026 | 306.85 | 312.57 | 306.85 | 309.57 | 774,500 |
| 25 September 2026 | 308.24 | 312.30 | 306.55 | 309.64 | 821,500 |
| 24 September 2026 | 304.62 | 309.54 | 303.13 | 308.95 | 784,900 |
| 23 September 2026 | 311.91 | 312.82 | 303.50 | 303.98 | 909,200 |
| 22 September 2026 | 303.46 | 316.53 | 303.46 | 311.54 | 2M |
| 21 September 2026 | 321.95 | 323.84 | 318.94 | 320.99 | 487,400 |
| 18 September 2026 | 322.00 | 322.70 | 319.38 | 320.71 | 2M |
| 17 September 2026 | 326.79 | 326.79 | 321.40 | 322.73 | 559,900 |
| 16 September 2026 | 323.51 | 325.30 | 320.38 | 324.51 | 561,400 |
| 15 September 2026 | 314.09 | 327.95 | 309.63 | 323.97 | 878,300 |
| 14 September 2026 | 314.12 | 316.49 | 308.21 | 315.31 | 707,800 |